Cell-Penetrating Pepducin Therapy Targeting PAR1 in Subjects With Coronary Artery Disease

Pepducins are membrane-tethered, cell-penetrating lipopeptides that target the cytoplasmic surface of their cognate receptor. Here, we report the first human use of a protease-activated receptor-1-based pepducin, which is intended as an antiplatelet agent to prevent ischemic complications of percuta...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Arteriosclerosis, thrombosis, and vascular biology Ročník 36; číslo 1; s. 189
Hlavní autori:	Gurbel, Paul A, Bliden, Kevin P, Turner, Susan E, Tantry, Udaya S, Gesheff, Martin G, Barr, Travis P, Covic, Lidija, Kuliopulos, Athan
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States 01.01.2016
Predmet:	Adult Aged Blood Platelets - drug effects Blood Platelets - metabolism Cell-Penetrating Peptides - administration & dosage Cell-Penetrating Peptides - adverse effects Cell-Penetrating Peptides - pharmacokinetics Coronary Artery Disease - blood Coronary Artery Disease - diagnosis Coronary Artery Disease - therapy Dose-Response Relationship, Drug Female Half-Life Humans Infusions, Intravenous Lipopeptides - administration & dosage Lipopeptides - adverse effects Lipopeptides - pharmacokinetics Male Middle Aged Percutaneous Coronary Intervention - adverse effects Platelet Aggregation - drug effects Platelet Aggregation Inhibitors - administration & dosage Platelet Aggregation Inhibitors - adverse effects Platelet Aggregation Inhibitors - pharmacokinetics Platelet Function Tests Receptor, PAR-1 - antagonists & inhibitors Receptor, PAR-1 - metabolism Treatment Outcome coronary artery disease collagen aspirin risk factors lipopeptides
ISSN:	1524-4636, 1524-4636
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Abstract	Pepducins are membrane-tethered, cell-penetrating lipopeptides that target the cytoplasmic surface of their cognate receptor. Here, we report the first human use of a protease-activated receptor-1-based pepducin, which is intended as an antiplatelet agent to prevent ischemic complications of percutaneous coronary interventions. PZ-128 was administered by 1 to 2 hours continuous intravenous infusion (0.01-2 mg/kg) to 31 subjects with coronary artery disease or multiple coronary artery disease risk factors. Safety, antiplatelet efficacy, and pharmacokinetics were assessed at baseline and 0.5, 1, 2, 6, 24 hours, and 7 to 10 days postdosing. The inhibitory effects of PZ-128 on platelet aggregation stimulated by the protease-activated receptor-1 agonist SFLLRN (8 μmol/L) at 30 minutes to 6 hours were dose dependent with 20% to 40% inhibition at 0.3 mg/kg, 40% to 60% at 0.5 mg/kg, and ≥ 80% to 100% at 1 to 2 mg/kg. The subgroup receiving aspirin in the 0.5 and 1-mg/kg dose cohorts had 65% to 100% inhibition of final aggregation to SFLLRN at 30 minutes to 2 hours and 95% to 100% inhibition by 6 hours. The inhibitory effects of 0.5 mg/kg PZ-128 were reversible with 50% recovery of aggregation to SFLLRN by 24 hours. There were no significant effects of PZ-128 on aggregation induced by AYPGKF, ADP, or collagen, indicating that the observed effects were specific to protease-activated receptor-1. The plasma half-life was 1.3 to 1.8 hours, and PZ-128 was nondetectable in urine. There were no effects on bleeding, coagulation, clinical chemistry, or ECG parameters. PZ-128 is a promising antiplatelet agent that provides rapid, specific, dose dependent, and reversible inhibition of platelet protease-activated receptor-1 through a novel intracellular mechanism. URL: http://www.clinicaltrials.gov. Unique identifier: NCT01806077.
AbstractList	Pepducins are membrane-tethered, cell-penetrating lipopeptides that target the cytoplasmic surface of their cognate receptor. Here, we report the first human use of a protease-activated receptor-1-based pepducin, which is intended as an antiplatelet agent to prevent ischemic complications of percutaneous coronary interventions.OBJECTIVEPepducins are membrane-tethered, cell-penetrating lipopeptides that target the cytoplasmic surface of their cognate receptor. Here, we report the first human use of a protease-activated receptor-1-based pepducin, which is intended as an antiplatelet agent to prevent ischemic complications of percutaneous coronary interventions.PZ-128 was administered by 1 to 2 hours continuous intravenous infusion (0.01-2 mg/kg) to 31 subjects with coronary artery disease or multiple coronary artery disease risk factors. Safety, antiplatelet efficacy, and pharmacokinetics were assessed at baseline and 0.5, 1, 2, 6, 24 hours, and 7 to 10 days postdosing. The inhibitory effects of PZ-128 on platelet aggregation stimulated by the protease-activated receptor-1 agonist SFLLRN (8 μmol/L) at 30 minutes to 6 hours were dose dependent with 20% to 40% inhibition at 0.3 mg/kg, 40% to 60% at 0.5 mg/kg, and ≥ 80% to 100% at 1 to 2 mg/kg. The subgroup receiving aspirin in the 0.5 and 1-mg/kg dose cohorts had 65% to 100% inhibition of final aggregation to SFLLRN at 30 minutes to 2 hours and 95% to 100% inhibition by 6 hours. The inhibitory effects of 0.5 mg/kg PZ-128 were reversible with 50% recovery of aggregation to SFLLRN by 24 hours. There were no significant effects of PZ-128 on aggregation induced by AYPGKF, ADP, or collagen, indicating that the observed effects were specific to protease-activated receptor-1. The plasma half-life was 1.3 to 1.8 hours, and PZ-128 was nondetectable in urine. There were no effects on bleeding, coagulation, clinical chemistry, or ECG parameters.APPROACH AND RESULTSPZ-128 was administered by 1 to 2 hours continuous intravenous infusion (0.01-2 mg/kg) to 31 subjects with coronary artery disease or multiple coronary artery disease risk factors. Safety, antiplatelet efficacy, and pharmacokinetics were assessed at baseline and 0.5, 1, 2, 6, 24 hours, and 7 to 10 days postdosing. The inhibitory effects of PZ-128 on platelet aggregation stimulated by the protease-activated receptor-1 agonist SFLLRN (8 μmol/L) at 30 minutes to 6 hours were dose dependent with 20% to 40% inhibition at 0.3 mg/kg, 40% to 60% at 0.5 mg/kg, and ≥ 80% to 100% at 1 to 2 mg/kg. The subgroup receiving aspirin in the 0.5 and 1-mg/kg dose cohorts had 65% to 100% inhibition of final aggregation to SFLLRN at 30 minutes to 2 hours and 95% to 100% inhibition by 6 hours. The inhibitory effects of 0.5 mg/kg PZ-128 were reversible with 50% recovery of aggregation to SFLLRN by 24 hours. There were no significant effects of PZ-128 on aggregation induced by AYPGKF, ADP, or collagen, indicating that the observed effects were specific to protease-activated receptor-1. The plasma half-life was 1.3 to 1.8 hours, and PZ-128 was nondetectable in urine. There were no effects on bleeding, coagulation, clinical chemistry, or ECG parameters.PZ-128 is a promising antiplatelet agent that provides rapid, specific, dose dependent, and reversible inhibition of platelet protease-activated receptor-1 through a novel intracellular mechanism.CONCLUSIONSPZ-128 is a promising antiplatelet agent that provides rapid, specific, dose dependent, and reversible inhibition of platelet protease-activated receptor-1 through a novel intracellular mechanism.URL: http://www.clinicaltrials.gov. Unique identifier: NCT01806077.CLINICAL TRIAL REGISTRATIONURL: http://www.clinicaltrials.gov. Unique identifier: NCT01806077. Pepducins are membrane-tethered, cell-penetrating lipopeptides that target the cytoplasmic surface of their cognate receptor. Here, we report the first human use of a protease-activated receptor-1-based pepducin, which is intended as an antiplatelet agent to prevent ischemic complications of percutaneous coronary interventions. PZ-128 was administered by 1 to 2 hours continuous intravenous infusion (0.01-2 mg/kg) to 31 subjects with coronary artery disease or multiple coronary artery disease risk factors. Safety, antiplatelet efficacy, and pharmacokinetics were assessed at baseline and 0.5, 1, 2, 6, 24 hours, and 7 to 10 days postdosing. The inhibitory effects of PZ-128 on platelet aggregation stimulated by the protease-activated receptor-1 agonist SFLLRN (8 μmol/L) at 30 minutes to 6 hours were dose dependent with 20% to 40% inhibition at 0.3 mg/kg, 40% to 60% at 0.5 mg/kg, and ≥ 80% to 100% at 1 to 2 mg/kg. The subgroup receiving aspirin in the 0.5 and 1-mg/kg dose cohorts had 65% to 100% inhibition of final aggregation to SFLLRN at 30 minutes to 2 hours and 95% to 100% inhibition by 6 hours. The inhibitory effects of 0.5 mg/kg PZ-128 were reversible with 50% recovery of aggregation to SFLLRN by 24 hours. There were no significant effects of PZ-128 on aggregation induced by AYPGKF, ADP, or collagen, indicating that the observed effects were specific to protease-activated receptor-1. The plasma half-life was 1.3 to 1.8 hours, and PZ-128 was nondetectable in urine. There were no effects on bleeding, coagulation, clinical chemistry, or ECG parameters. PZ-128 is a promising antiplatelet agent that provides rapid, specific, dose dependent, and reversible inhibition of platelet protease-activated receptor-1 through a novel intracellular mechanism. URL: http://www.clinicaltrials.gov. Unique identifier: NCT01806077.
Author	Kuliopulos, Athan Gurbel, Paul A Barr, Travis P Turner, Susan E Gesheff, Martin G Covic, Lidija Bliden, Kevin P Tantry, Udaya S
Author_xml	– sequence: 1 givenname: Paul A surname: Gurbel fullname: Gurbel, Paul A organization: From the Sinai Center for Thrombosis Research, Sinai Hospital of Baltimore, MD (P.A.G., K.P.B., U.S.T., M.G.G.); and the Center for Hemostasis and Thrombosis Research, MORI, Tufts Medical Center, Boston, MA (S.E.T., T.P.B., L.C., A.K.) – sequence: 2 givenname: Kevin P surname: Bliden fullname: Bliden, Kevin P organization: From the Sinai Center for Thrombosis Research, Sinai Hospital of Baltimore, MD (P.A.G., K.P.B., U.S.T., M.G.G.); and the Center for Hemostasis and Thrombosis Research, MORI, Tufts Medical Center, Boston, MA (S.E.T., T.P.B., L.C., A.K.) – sequence: 3 givenname: Susan E surname: Turner fullname: Turner, Susan E organization: From the Sinai Center for Thrombosis Research, Sinai Hospital of Baltimore, MD (P.A.G., K.P.B., U.S.T., M.G.G.); and the Center for Hemostasis and Thrombosis Research, MORI, Tufts Medical Center, Boston, MA (S.E.T., T.P.B., L.C., A.K.) – sequence: 4 givenname: Udaya S surname: Tantry fullname: Tantry, Udaya S organization: From the Sinai Center for Thrombosis Research, Sinai Hospital of Baltimore, MD (P.A.G., K.P.B., U.S.T., M.G.G.); and the Center for Hemostasis and Thrombosis Research, MORI, Tufts Medical Center, Boston, MA (S.E.T., T.P.B., L.C., A.K.) – sequence: 5 givenname: Martin G surname: Gesheff fullname: Gesheff, Martin G organization: From the Sinai Center for Thrombosis Research, Sinai Hospital of Baltimore, MD (P.A.G., K.P.B., U.S.T., M.G.G.); and the Center for Hemostasis and Thrombosis Research, MORI, Tufts Medical Center, Boston, MA (S.E.T., T.P.B., L.C., A.K.) – sequence: 6 givenname: Travis P surname: Barr fullname: Barr, Travis P organization: From the Sinai Center for Thrombosis Research, Sinai Hospital of Baltimore, MD (P.A.G., K.P.B., U.S.T., M.G.G.); and the Center for Hemostasis and Thrombosis Research, MORI, Tufts Medical Center, Boston, MA (S.E.T., T.P.B., L.C., A.K.) – sequence: 7 givenname: Lidija surname: Covic fullname: Covic, Lidija organization: From the Sinai Center for Thrombosis Research, Sinai Hospital of Baltimore, MD (P.A.G., K.P.B., U.S.T., M.G.G.); and the Center for Hemostasis and Thrombosis Research, MORI, Tufts Medical Center, Boston, MA (S.E.T., T.P.B., L.C., A.K.) – sequence: 8 givenname: Athan surname: Kuliopulos fullname: Kuliopulos, Athan email: athan.kuliopulos@tufts.edu organization: From the Sinai Center for Thrombosis Research, Sinai Hospital of Baltimore, MD (P.A.G., K.P.B., U.S.T., M.G.G.); and the Center for Hemostasis and Thrombosis Research, MORI, Tufts Medical Center, Boston, MA (S.E.T., T.P.B., L.C., A.K.). athan.kuliopulos@tufts.edu
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/26681756$$D View this record in MEDLINE/PubMed
BookMark	eNpNUEtLw0AYXESxD_0DHiRHL6n7ym73GOOjQsGiUfEU9vG1TWmTuJsc-u-NtIKnmY8Zhm9mhE6rugKErgieECLIbZp_3KWztD-SCcNCSnmChiShPOaCidN_fIBGIWwwxpxSfI4GVIgpkYkYoq8Mttt4ARW0XrdltYoW0LjOllWUr8HrZh_l2q_gIKWvJOqVt85swLYh-izbdZTVvq6030epb6GH-zKADnCBzpZ6G-DyiGP0_viQZ7N4_vL0nKXz2HKuZKwMl4wuJXWMEKxAc-eWdmqso5RpClgZObUCS5YIQ62UThHmwBjumFGY0DG6OeQ2vv7uILTFrgy2b6UrqLtQ9D2JUkLwX-v10dqZHbii8eWuf7z4m4P-AJXOY7c
CitedBy_id	crossref_primary_10_1146_annurev_pharmtox_011613_140016 crossref_primary_10_3390_membranes11120919 crossref_primary_10_1080_14656566_2018_1457649 crossref_primary_10_1016_j_jconrel_2019_07_020 crossref_primary_10_1038_s41586_018_0259_z crossref_primary_10_1016_j_thromres_2020_08_004 crossref_primary_10_1038_s41573_020_0062_z crossref_primary_10_3390_ijms222313079 crossref_primary_10_1016_j_pharmthera_2020_107529 crossref_primary_10_3390_ijms26010059 crossref_primary_10_3390_jcdd9110397 crossref_primary_10_1042_BST20150282 crossref_primary_10_1016_j_ejmech_2021_113867 crossref_primary_10_1177_1074248419899314 crossref_primary_10_3892_mmr_2017_7537 crossref_primary_10_1016_j_tips_2017_05_001 crossref_primary_10_1093_molehr_gax068 crossref_primary_10_1111_jth_13374 crossref_primary_10_1186_s12959_019_0194_8 crossref_primary_10_3389_fphar_2021_769021 crossref_primary_10_1038_s41569_023_00854_6 crossref_primary_10_3390_biomedicines11071971 crossref_primary_10_1136_heartjnl_2014_306695 crossref_primary_10_1002_rth2_12115 crossref_primary_10_3389_fnmol_2019_00273 crossref_primary_10_1002_cmdc_201800793 crossref_primary_10_1016_j_ccell_2018_03_002 crossref_primary_10_3390_ijms25147575 crossref_primary_10_1074_jbc_M116_732743 crossref_primary_10_1016_j_jbc_2021_101057 crossref_primary_10_1016_j_tibs_2018_04_003 crossref_primary_10_3390_ijms232314914 crossref_primary_10_3390_ijms24076187 crossref_primary_10_3390_pharmaceutics12030225 crossref_primary_10_1016_j_bmc_2018_04_016 crossref_primary_10_3389_fonc_2022_939089 crossref_primary_10_1080_13543784_2020_1708324 crossref_primary_10_1161_ATVBAHA_120_315837 crossref_primary_10_1161_ATVBAHA_125_323140 crossref_primary_10_1016_j_jtha_2023_08_029 crossref_primary_10_1002_rth2_12403 crossref_primary_10_1038_nrrheum_2018_17 crossref_primary_10_1161_ATVBAHA_118_310967 crossref_primary_10_1080_17474086_2023_2227788 crossref_primary_10_1111_febs_15829 crossref_primary_10_1007_s10557_021_07299_4 crossref_primary_10_1016_j_phrs_2020_104750 crossref_primary_10_1016_j_bbagen_2019_07_007 crossref_primary_10_1161_ATVBAHA_120_315168 crossref_primary_10_3390_ijms19082237 crossref_primary_10_1016_j_bcmd_2018_07_004 crossref_primary_10_1161_CIRCHEARTFAILURE_123_010621 crossref_primary_10_1016_j_ejmech_2020_112893 crossref_primary_10_1038_s41573_020_0061_0 crossref_primary_10_1007_s10989_020_10066_y crossref_primary_10_1016_j_jid_2018_08_019 crossref_primary_10_1002_rth2_12454 crossref_primary_10_1097_FJC_0000000000001236 crossref_primary_10_1016_j_bbamem_2016_08_013 crossref_primary_10_1007_s10555_017_9679_8 crossref_primary_10_3390_molecules24050927 crossref_primary_10_3389_fchem_2021_671483 crossref_primary_10_1161_ATVBAHA_118_310224 crossref_primary_10_1161_CIRCRESAHA_117_310939 crossref_primary_10_1016_j_tips_2018_03_002
ContentType	Journal Article
Copyright	2015 American Heart Association, Inc.
Copyright_xml	– notice: 2015 American Heart Association, Inc.
DBID	CGR CUY CVF ECM EIF NPM 7X8
DOI	10.1161/ATVBAHA.115.306777
DatabaseName	Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic MEDLINE
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	no_fulltext_linktorsrc
Discipline	Medicine
EISSN	1524-4636
ExternalDocumentID	26681756
Genre	Journal Article Clinical Trial, Phase I Research Support, N.I.H., Extramural
GrantInformation_xml	– fundername: NHLBI NIH HHS grantid: P50 HL110789
GroupedDBID	--- .3C .55 .GJ .Z2 01R 0R~ 1J1 23N 2WC 3O- 40H 4Q1 4Q2 4Q3 53G 5GY 5RE 5VS 71W 77Y 7O~ AAAAV AAAXR AAGIX AAHPQ AAIQE AAMOA AAMTA AAQKA AARTV AASCR AASOK AAXQO ABASU ABBUW ABDIG ABJNI ABQRW ABVCZ ABXVJ ABZAD ABZZY ACCJW ACDDN ACEWG ACGFS ACGOD ACIJW ACILI ACLDA ACPRK ACWDW ACWRI ACXJB ACXNZ ACZKN ADBBV ADFPA ADGGA ADHPY ADNKB AE3 AE6 AEETU AENEX AFBFQ AFDTB AFFNX AFUWQ AGINI AHJKT AHMBA AHOMT AHQNM AHRYX AHVBC AIJEX AINUH AJCLO AJIOK AJNWD AJNYG AJZMW AKCTQ AKULP ALKUP ALMA_UNASSIGNED_HOLDINGS ALMTX AMJPA AMKUR AMNEI AOHHW AOQMC AYCSE BAWUL BOYCO BQLVK BS7 C1A C45 CGR CS3 CUY CVF DIK DIWNM DUNZO E.X E3Z EBS ECM EEVPB EIF EJD ERAAH EX3 F2K F2L F2M F2N F5P FCALG FL- FRP FW0 GNXGY GQDEL GX1 H0~ H13 HLJTE HZ~ IKREB IKYAY IN~ IPNFZ J5H JF9 JG8 JK3 JK8 K8S KD2 KMI KQ8 L-C L7B N9A NPM N~7 N~B N~M O9- OAG OAH OB2 OCUKA ODA OL1 OLG OLH OLU OLV OLY OLZ OPUJH ORVUJ OUVQU OVD OVDNE OVIDH OVLEI OWU OWV OWW OWX OWY OWZ OXXIT P-K P2P PQQKQ PZZ RAH RIG RLZ S4R S4S T8P TEORI TR2 TSPGW V2I VVN W3M W8F WOQ WOW X3V X3W X7M XXN XYM YFH ZGI ZZMQN 7X8 ABPXF ACBKD ADKSD ADSXY
ID	FETCH-LOGICAL-c4497-9b4732f72d31109ea4ddfc8bcd223a2e09b78c607356b2c77d913debb4d3b9012
IEDL.DBID	7X8
ISICitedReferencesCount	81
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000367000000023&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1524-4636
IngestDate	Sun Nov 09 10:12:28 EST 2025 Thu Apr 03 07:04:40 EDT 2025
IsDoiOpenAccess	false
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	1
Keywords	coronary artery disease collagen aspirin risk factors lipopeptides
Language	English
License	2015 American Heart Association, Inc.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c4497-9b4732f72d31109ea4ddfc8bcd223a2e09b78c607356b2c77d913debb4d3b9012
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
OpenAccessLink	https://www.ahajournals.org/doi/pdf/10.1161/ATVBAHA.115.306777
PMID	26681756
PQID	1751996641
PQPubID	23479
ParticipantIDs	proquest_miscellaneous_1751996641 pubmed_primary_26681756
PublicationCentury	2000
PublicationDate	2016-January
PublicationDateYYYYMMDD	2016-01-01
PublicationDate_xml	– month: 01 year: 2016 text: 2016-January
PublicationDecade	2010
PublicationPlace	United States
PublicationPlace_xml	– name: United States
PublicationTitle	Arteriosclerosis, thrombosis, and vascular biology
PublicationTitleAlternate	Arterioscler Thromb Vasc Biol
PublicationYear	2016
References	21502577 - Circulation. 2011 May 3;123(17):1843-53 23890998 - Lancet. 2013 Aug 17;382(9892):614-23 25633316 - Arterioscler Thromb Vasc Biol. 2015 Mar;35(3):500-12 10421606 - Circulation. 1999 Jul 27;100(4):437-44 19286091 - Lancet. 2009 Mar 14;373(9667):919-28 20805115 - Eur Heart J. 2010 Nov;31(21):2601-13 24216752 - Nat Med. 2013 Dec;19(12):1609-16 17965715 - Nat Immunol. 2007 Dec;8(12):1303-12 21053136 - Methods Mol Biol. 2011;683:259-75 21502571 - Circulation. 2011 May 3;123(17):1854-63 22705889 - Circulation. 2012 Jul 3;126(1):83-91 24076493 - J Am Coll Cardiol. 2013 Dec 17;62(24):2261-73 16505172 - Circulation. 2006 Mar 7;113(9):1244-54 15738352 - Circulation. 2005 Mar 8;111(9):1153-9 19717846 - N Engl J Med. 2009 Sep 10;361(11):1045-57 16286165 - J Am Coll Cardiol. 2005 Nov 15;46(10):1820-6 20439812 - Circulation. 2010 May 4;121(17):1960-70 25896078 - Eur Heart J. 2015 Jul 14;36(27):1762-71 22412089 - Circulation. 2012 Mar 13;125(10):1276-87; discussion 1287 15850609 - Thromb Res. 2005;116(1):55-66 24402559 - Thromb Haemost. 2014 May 5;111(5):883-91 11805322 - Proc Natl Acad Sci U S A. 2002 Jan 22;99(2):643-8 21364148 - Circ Cardiovasc Interv. 2011 Apr 1;4(2):171-9 22374997 - J Biol Chem. 2012 Apr 13;287(16):12787-96 16952995 - Circulation. 2006 Sep 5;114(10):1070-7 18818650 - Nature. 2008 Sep 25;455(7212):497-502 24268424 - Thromb Res. 2014 Jan;133(1):66-72 10926528 - Science. 2000 Aug 4;289(5480):739-45 22077816 - N Engl J Med. 2012 Jan 5;366(1):20-33 23222541 - Nature. 2012 Dec 20;492(7429):387-92 25600441 - Thromb Res. 2015 Mar;135(3):513-20 19379698 - Cell. 2009 Apr 17;137(2):332-43 25260718 - J Am Coll Cardiol. 2014 Dec 23;64(24):e139-228 25934391 - J Biol Chem. 2015 Jun 19;290(25):15785-98 12357249 - Nat Med. 2002 Oct;8(10):1161-5
References_xml	– reference: 22705889 - Circulation. 2012 Jul 3;126(1):83-91 – reference: 11805322 - Proc Natl Acad Sci U S A. 2002 Jan 22;99(2):643-8 – reference: 21502571 - Circulation. 2011 May 3;123(17):1854-63 – reference: 21053136 - Methods Mol Biol. 2011;683:259-75 – reference: 10926528 - Science. 2000 Aug 4;289(5480):739-45 – reference: 21502577 - Circulation. 2011 May 3;123(17):1843-53 – reference: 25260718 - J Am Coll Cardiol. 2014 Dec 23;64(24):e139-228 – reference: 18818650 - Nature. 2008 Sep 25;455(7212):497-502 – reference: 17965715 - Nat Immunol. 2007 Dec;8(12):1303-12 – reference: 23890998 - Lancet. 2013 Aug 17;382(9892):614-23 – reference: 24402559 - Thromb Haemost. 2014 May 5;111(5):883-91 – reference: 19379698 - Cell. 2009 Apr 17;137(2):332-43 – reference: 12357249 - Nat Med. 2002 Oct;8(10):1161-5 – reference: 24216752 - Nat Med. 2013 Dec;19(12):1609-16 – reference: 19717846 - N Engl J Med. 2009 Sep 10;361(11):1045-57 – reference: 25896078 - Eur Heart J. 2015 Jul 14;36(27):1762-71 – reference: 15850609 - Thromb Res. 2005;116(1):55-66 – reference: 25934391 - J Biol Chem. 2015 Jun 19;290(25):15785-98 – reference: 19286091 - Lancet. 2009 Mar 14;373(9667):919-28 – reference: 23222541 - Nature. 2012 Dec 20;492(7429):387-92 – reference: 25600441 - Thromb Res. 2015 Mar;135(3):513-20 – reference: 22412089 - Circulation. 2012 Mar 13;125(10):1276-87; discussion 1287 – reference: 20439812 - Circulation. 2010 May 4;121(17):1960-70 – reference: 16286165 - J Am Coll Cardiol. 2005 Nov 15;46(10):1820-6 – reference: 22374997 - J Biol Chem. 2012 Apr 13;287(16):12787-96 – reference: 16505172 - Circulation. 2006 Mar 7;113(9):1244-54 – reference: 22077816 - N Engl J Med. 2012 Jan 5;366(1):20-33 – reference: 25633316 - Arterioscler Thromb Vasc Biol. 2015 Mar;35(3):500-12 – reference: 10421606 - Circulation. 1999 Jul 27;100(4):437-44 – reference: 20805115 - Eur Heart J. 2010 Nov;31(21):2601-13 – reference: 24076493 - J Am Coll Cardiol. 2013 Dec 17;62(24):2261-73 – reference: 21364148 - Circ Cardiovasc Interv. 2011 Apr 1;4(2):171-9 – reference: 16952995 - Circulation. 2006 Sep 5;114(10):1070-7 – reference: 15738352 - Circulation. 2005 Mar 8;111(9):1153-9 – reference: 24268424 - Thromb Res. 2014 Jan;133(1):66-72
SSID	ssj0004220
Score	2.4686623
Snippet	Pepducins are membrane-tethered, cell-penetrating lipopeptides that target the cytoplasmic surface of their cognate receptor. Here, we report the first human...
SourceID	proquest pubmed
SourceType	Aggregation Database Index Database
StartPage	189
SubjectTerms	Adult Aged Blood Platelets - drug effects Blood Platelets - metabolism Cell-Penetrating Peptides - administration & dosage Cell-Penetrating Peptides - adverse effects Cell-Penetrating Peptides - pharmacokinetics Coronary Artery Disease - blood Coronary Artery Disease - diagnosis Coronary Artery Disease - therapy Dose-Response Relationship, Drug Female Half-Life Humans Infusions, Intravenous Lipopeptides - administration & dosage Lipopeptides - adverse effects Lipopeptides - pharmacokinetics Male Middle Aged Percutaneous Coronary Intervention - adverse effects Platelet Aggregation - drug effects Platelet Aggregation Inhibitors - administration & dosage Platelet Aggregation Inhibitors - adverse effects Platelet Aggregation Inhibitors - pharmacokinetics Platelet Function Tests Receptor, PAR-1 - antagonists & inhibitors Receptor, PAR-1 - metabolism Treatment Outcome
Title	Cell-Penetrating Pepducin Therapy Targeting PAR1 in Subjects With Coronary Artery Disease
URI	https://www.ncbi.nlm.nih.gov/pubmed/26681756 https://www.proquest.com/docview/1751996641
Volume	36
WOSCitedRecordID	wos000367000000023&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings	1
isFullTextHit
isPrint
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3dS8MwEA_qRHzx-2N-UcHXuDVJk-ZJ6nTsZaNI1flUmibVwejmugn-917aDn0RBF8ayhFajsvdj7vL7xC60h7VkmcZFjTjmCk_wZLYKrvixkDM0YRn5bAJMRj4w6EM64RbUbdVLn1i6aj1JLU58haEOdswy5l7M33HdmqUra7WIzRWUYMClLFWLYY_2MJJScsIIYphS4y1vDTD3VYQPd0GvQBevGuLmoX4HWKWoaa7_d-f3EFbNch0gsoqdtGKyffQRr8uo--jl44Zj3EIbq4kzc1fndBM9QKETlSxDDhR2SFeioIH1wEJuBibsymc59H8zelY5oNk9mk_YmC5qwo9B-ixex91eriesYBTxqTAUjFBSSaIppZ71CRM6yz1VaoBNyTEtKUSfsrBEXhckVQILV2qjVJMUwVYghyitXySm2PkUGOJZNoebJVMUpVk9tKu7xGjmK-paKLLpdJisGFbmEhyM1kU8bfamuio0nw8rcg2YgAQPsj5yR92n6JNwDN1huQMNTI4weYcracf81ExuyiNA56DsP8FyiTCdQ
linkProvider	ProQuest
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Cell-Penetrating+Pepducin+Therapy+Targeting+PAR1+in+Subjects+With+Coronary+Artery+Disease&rft.jtitle=Arteriosclerosis%2C+thrombosis%2C+and+vascular+biology&rft.au=Gurbel%2C+Paul+A&rft.au=Bliden%2C+Kevin+P&rft.au=Turner%2C+Susan+E&rft.au=Tantry%2C+Udaya+S&rft.date=2016-01-01&rft.eissn=1524-4636&rft.volume=36&rft.issue=1&rft.spage=189&rft_id=info:doi/10.1161%2FATVBAHA.115.306777&rft_id=info%3Apmid%2F26681756&rft_id=info%3Apmid%2F26681756&rft.externalDocID=26681756
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1524-4636&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1524-4636&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1524-4636&client=summon